BTK inhibitors do not significantly increase second primary malignancy risk in B-cell lymphoma patients
BTK inhibitors do not appear to cause second primary cancers
This meta-analysis of 9337 patients found that BTK inhibitors do not significantly increase the risk of second primary malignancies compared…
New data suggests that a common class of drugs used to treat certain blood cancers does not increase the risk of developing new cancers.
Pirtobrutinib Combined with Venetoclax and Rituximab Improves Progression Free Survival
Trial shows pirtobrutinib improves survival for chronic lymphocytic leukemia
Adding pirtobrutinib to a venetoclax-rituximab regimen significantly extends progression-free survival in patients with chronic lymphocytic …
A new combination treatment involving pirtobrutinib may help patients with chronic lymphocytic leukemia live longer without their cancer pro…
Venetoclax-based combinations show superior progression-free survival compared to chemoimmunotherapy in CLL without TP53 aberrations
Trial shows venetoclax combinations improve progression-free survival in CLL
This Phase 3 randomized controlled trial of 926 patients with CLL without TP53 aberrations found that venetoclax-based regimens (RV, GV, and…
New clinical trial results show that specific venetoclax combinations can keep chronic lymphocytic leukemia stable for longer than standard …
Rate of drug concentration rise alters hemodynamic responses and mortality risk in coronary heart disease patients
New analysis shows how fast drug levels change affects patient safety outcomes
This narrative review and theoretical framework synthesizes evidence on rate-dependent pharmacology. It highlights divergent hemodynamic res…
This review explains that how quickly medicine levels rise in the body matters for safety. Fast changes can cause more harm than slow ones, …
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies
Idiotype-directed CAAR-T therapy remains a hypothesis for B-cell malignancies
This narrative review discusses idiotype-directed CAAR-T therapy for B-cell malignancies including chronic lymphocytic leukemia and indolent…
A narrative review suggests idiotype-directed CAAR-T therapy is a theoretical option for B-cell cancers, not a current treatment.
Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL
Zanubrutinib outperforms combo therapy for early leukemia
This post hoc indirect comparison analyzed treatment-naive chronic lymphocytic leukemia patients without del(17p) from phase 3 RCTs.
A single pill for early leukemia may work better than taking multiple drugs, offering a simpler and more effective option for patients who w…
Ibrutinib monotherapy showed durable progression-free survival in patients with TP53 aberrations or advanced age
Ten Years on One Pill: What Long-Term Ibrutinib Revealed
This investigator-sponsored phase 2 study evaluated single-agent ibrutinib in 84 patients with chronic lymphocytic leukemia (CLL) harboring …
A decade of follow-up shows a daily pill can give high-risk leukemia patients years of control, but staying on it is not easy.
Case report: obinutuzumab and venetoclax associated with nephrotic syndrome resolution in two CLL patients
Two CLL patients saw kidney condition improve after targeted cancer treatment
A case report describes two patients with chronic lymphocytic leukemia (CLL) and concomitant nephrotic syndrome.
Two CLL patients saw kidney problems improve after targeted cancer treatment, resolving symptoms and reducing urine protein within weeks.
Research across Leukemia
Related studies from across the Leukemia family.
Early genetic diagnosis of inherited bone marrow failure syndromes facilitates timely transplant and lifelong surveillance
Genetic Factors May Influence Diagnosis of Bone Marrow Failure
This narrative review explores the pathogenesis, clinical manifestations, and management of pediatric patients with inherited bone marrow fa…
Genetic factors can be the hidden cause of bone marrow failure in children, making early genetic testing vital for proper treatment and plan…
Positive LSC status is associated with inferior survival outcomes in patients with acute myeloid leukemia
Leukemia Stem Cell Counts Help Doctors Predict Patient Survival Outcomes
This systematic review and reconstructed individual patient data meta-analysis analyzed survival outcomes in patients with acute myeloid leu…
Testing for specific leukemia stem cells can help doctors predict how well a patient will do during treatment.
Icotinib treatment for EGFR-mutated NSCLC may be associated with rare treatment-related myeloid neoplasm
Icotinib Treatment for Lung Cancer Linked to Rare Blood Condition
This case report and literature review describes a 75-year-old female with lung adenocarcinoma treated with icotinib. The report identifies …
A rare case of acute myeloid leukemia was linked to a specific lung cancer treatment, highlighting the need for regular blood monitoring.
Chemotherapy-Free Ponatinib Plus Blinatumomab Beats Imatinib in Ph-Positive ALL
Trial shows ponatinib and blinatumomab improve outcomes for Philadelphia-positive ALL
In Ph-positive ALL, frontline ponatinib plus blinatumomab achieved 86% 24-month event-free survival versus 67% with imatinib plus chemothera…
A new combination of ponatinib and blinatumomab showed higher survival rates and fewer relapses for adults with Philadelphia-positive ALL.
VRE Prevalence 18.4% in Hematologic Malignancy Patients, Pooled Meta-Analysis Finds
Vancomycin-resistant Enterococcus is common in patients with certain blood cancers
This meta-analysis of 120 studies estimates the pooled prevalence of vancomycin-resistant Enterococcus (VRE) in patients with hematological …
A large review of 120 studies shows that nearly 1 in 5 patients with leukemia or lymphoma carry a resistant strain of bacteria.
Low-dose chemotherapy shows no difference in remission but worse outcomes in KIT-mutated AML
Low-dose chemotherapy shows similar results for some children with leukemia
This retrospective secondary analysis of a multicenter randomized controlled trial evaluated low-dose chemotherapy (LDC) versus standard-dos…
A study of children with a specific type of leukemia found that lower doses of chemotherapy can be as effective as standard doses for many p…
Dasatinib therapy in pediatric ALL may cause chylothorax and Bartonella henselae infection
Dasatinib May Cause Chylothorax and Cat-Scratch Disease in Leukemia
This case report and systematic review describes a 14-year-old boy with Ph+ acute lymphoblastic leukemia treated with dasatinib who develope…
A 14-year-old on dasatinib for leukemia developed chylothorax and cat-scratch disease, a rare double complication.
Blinatumomab Improves Four Year Event Free Survival in Pediatric High Risk B Cell ALL
Trial shows blinatumomab improves survival for children with high-risk leukemia
Blinatumomab significantly improves 4-year event-free survival in children with high-risk B-cell ALL compared to standard chemotherapy.
A new trial shows that blinatumomab helps more children with high-risk B-cell leukemia stay healthy compared to standard chemotherapy.
Busulfan-based conditioning favors survival in AML while TBI yields better outcomes in ALL
Busulfan Shows Survival Benefits for Patients with Acute Myeloid Leukemia
This meta-analysis of 26 studies compared Busulfan-based conditioning to total body irradiation for children and young adults undergoing hem…
Busulfan may offer better survival for certain leukemias while reducing long-term side effects like growth issues and cataracts in young pat…
Exercise interventions improve bone mineral density, cardiorespiratory endurance, and quality of life in children with acute leukemia
Exercise May Help Kids With Leukemia Feel and Move Better
This best evidence summary synthesizes 16 systematic reviews and 2 clinical practice guidelines regarding exercise interventions for childre…
Exercise may improve bone strength, fitness, and quality of life in children with acute leukemia, a new evidence summary suggests.
MRG mutations correlate with worse overall survival and lower remission in NPM1-mutated AML
Specific gene mutations linked to worse outcomes in certain leukemia
This meta-analysis of 4,363 patients found that MRG mutations (such as ASXL1, BCOR, and EZH2) are associated with inferior overall survival …
New data shows that specific gene mutations can predict poorer survival and lower remission rates for patients with a specific type of leuke…
Treosulfan-fludarabine improves 24-month event-free survival to 65% versus 53% in AML patients
Treosulfan Shows Better Outcomes for Patients with Acute Myeloid Leukemia
This Phase 3 randomized trial subgroup analysis of 352 patients with AML undergoing alloHCT found treosulfan-fludarabine superior to reduced…
A new analysis of a Phase 3 trial suggests treosulfan may offer better survival rates and fewer complications for patients with acute myeloi…